Anti-infection of Low-does IL-2 in SLE
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02932137 |
Recruitment Status :
Completed
First Posted : October 13, 2016
Last Update Posted : March 15, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Systemic Lupus Erythematosus | Drug: Interleukin-2 | Not Applicable |
Systemic lupus erythematosus (SLE) is a chronic autoimmune syndrome affecting various organs.Many feel that glucocorticoid and immunosuppressor are the standard therapy for patients with SLE. While it can improve the risk of infection among SLE patients. A novel therapy to treat SLE with low-does IL-2 has been identified recently. IL-2 also used to against some virus infect. So we hypothesized that low-dose IL-2 could reduce risk of infection in SLE patients.
Methods: A total of SLE patients (n=30) were divided into two groups randomly. One received standard therapy, while another one administrate with low-does IL-2 plus standard therapy.Each patient will be treated with low-dose IL-2. The end points are clinical and immunologic response.
Expected Results: This trail wlii provide both clinical and basic profe that low-dose IL-2 plus standard therapy have lower infection risk in SLE patients.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Potential Effect of Anti-infection by Low-dose IL-2 in Treatment of SLE |
Actual Study Start Date : | May 5, 2016 |
Actual Primary Completion Date : | December 16, 2016 |
Actual Study Completion Date : | August 30, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Interleukin-2
Interleukin-2 to treat activated SLE.
|
Drug: Interleukin-2
Patients receive low dose recombinant human Interleukin-2(HrIL-2)
Other Name: Recombinant Human Interleukin-2,125Ala, SL Pharm |
No Intervention: Traditional therapy
Treat activated SLE with glucocorticoid or immunosuppressor.
|
- Immunological Responses [ Time Frame: week 0 and week 10 ]The increased intracellular factors which could reflect the organic immunity
- Virus titers [ Time Frame: week 0 and week 10 ]The reduced titers of virus in SLE patients
- SLEDAI Score [ Time Frame: week 0 and week 10 ]Assessment version of the SLE Disease Activity Index (SELENA-SLEDAI) change.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Meet the American College of Rheumatology criteria for the diagnosis of SLE.
- Under standard treatment (≥ 2 months) at the time of inclusion
- Background treatment failed to control flares or to permit prednisone tapering
- With at least one of the following manifestations: thrombocytopenia, disease-associated rash, mouth ulcer, non-infectious type of fever, active vasculitis, renal disorder(proteinuria>0.5g/day), neuropsychiatric SLE.
- Positive for at least one of the following laboratory tests: ANA>1:160, anti-dsDNA, immunoglobulin>20g/L, decreased C3 or C4, leukopenia<3×10^9/L, thrombocytopenia<100×10^9/L;
- SLE disease activity index(SLEDAI) ≥ 8.
- Negative HIV test.
- Negative for hepatitis B and C virus.
- Written informed consent form.
Exclusion Criteria:
- Sever chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III NYHA), hepatic insufficiency (transaminases> 3N) )
- Serious infection such as bacteremia, sepsis;
- Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or Basocellular carcinoma);
- High-dose steroid pulse therapy (>1.5mg/kg) or IV bolus of corticosteroids in the last 2 months.
- History of administration of rituximab or other biologics;
- Purified protein derivative (tuberculin) >10mm
- Mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information;
- Inability to comply with IL-2 treatment regimen.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02932137
China, Beijing | |
Department of Rheumatology and Immunology, Peking University People's Hospital | |
Beijing, Beijing, China, 100044 |
Principal Investigator: | Zhanguo Li, MD and PhD | Peking University Institute of Rheumatology and Immunology |
Responsible Party: | Zhanguo Li, Professor and chief of department of rheumatology and immunology, Peking University People's Hospital |
ClinicalTrials.gov Identifier: | NCT02932137 |
Other Study ID Numbers: |
IL-2-20160505 |
First Posted: | October 13, 2016 Key Record Dates |
Last Update Posted: | March 15, 2018 |
Last Verified: | March 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
SLE,IL-2 |
Lupus Erythematosus, Systemic Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Interleukin-2 Antineoplastic Agents |
Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |